Evaluating the potential for respiratory metagenomics to improve treatment of secondary infection and detection of nosocomial transmission on expanded COVID-19 intensive care units.
Themoula CharalampousAdela Alcolea-MedinaLuke B SnellTom G S WilliamsRahul BatraChristopher AlderAndrea TelatinLuigi CamporotaChristopher I S MeadowsDuncan WyncollNicholas A BarrettCarolyn J HemsleyLisa BryanWilliam NewsholmeSara E BoydAnna GreenUla MahadevaAmita PatelPenelope R CliffAndrew J PageJustin O'GradyJonathan D EdgeworthPublished in: Genome medicine (2021)
CMg testing provides accurate pathogen detection and antibiotic resistance prediction in a same-day laboratory workflow, with assembled genomes available the next day for genomic surveillance. The provision of this technology in a service setting could fundamentally change the multi-disciplinary team approach to managing ICU infections. The potential to improve the initial targeted treatment and rapidly detect unsuspected outbreaks of MDR-pathogens justifies further expedited clinical assessment of CMg.
Keyphrases
- intensive care unit
- coronavirus disease
- sars cov
- palliative care
- public health
- loop mediated isothermal amplification
- multidrug resistant
- drug delivery
- mechanical ventilation
- label free
- human health
- cancer therapy
- methicillin resistant staphylococcus aureus
- pseudomonas aeruginosa
- risk assessment
- candida albicans
- quality improvement
- gram negative
- klebsiella pneumoniae